Vivos Therapeutics 2025 annual meeting elects directors, approves equity plan amendment, ratifies auditor

Vivos Therapeutics, Inc.

All six director nominees elected: Huntsman, Green, Krammer, Lindsay, Sokolow, Thompson; each with >2.6M votes for.
Amendment to 2024 Omnibus Equity Incentive Plan approved with 2.45M for, 516K against, 2.3K abstain.
Appointment of Baker Tilly US, LLP as auditor for FY ending Dec 31, 2025 ratified with 4.86M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.